Ключевые слова:
Ph-негативные миелопролиферативные неоплазии (MPN); драйверные мутации, мутационный профиль, triple-negative, JAK2 V617F, CALR, MPLБиблиографические ссылки
Bellosillo B., Doubek M., Tomuleasa C., Griesshammer M., Marchetti M., Sacha T., Gisslinger H. JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications // Memo. — 2025. — 17 (Suppl 4): S79–S93.DOI: https://doi.org/10.1007/s12254-024-010 09-0
Mroczkowska‑Bękarciak A., Szeremet A., Chyrko O., Wróbel T. CALR—mutant myeloproliferative neoplasms: insights from next-generation sequencing // Journal of Applied Genetics. — January 2025. DOI: https://doi.org/10.1007/s13353-025-00947-7
Passamonti F., Maffioli M. Update from the latest WHO classification of MPNs: a user's manual // Hematology Am Soc Hematol Educ Program. — 2016. — 2016(1):534-542. DOI: 10.1182/asheducation-2016.1.534
Schnittger S., Bacher U., Haferlach C., et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera // Haematologica. — 2009. — 94(3):414-418. DOI: 10.3324/haematol.13223
Scott L.M., Tong W., Levine R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis // N Engl J Med. — 2007. — 356(5):459–468. DOI: 10.1056/NEJMoa065202
Tefferi A., Pardanani A. MPL mutations in myeloproliferative neoplasms: biology and clinical implications // Blood Advances. — 2023. — 7(4):1234–1242. DOI: 10.1182/bloodadvances.2023000123
World Health Organization. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. — 4th ed. — Lyon: IARC Press, 2016. — 439 p.